secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-11-13T21:00:39+00:00
Accession:  0001493152-26-051693
Event type: litigation
Sentiment:  negative
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Tonix sues Dr. Reddy's over TONMYA generic; ANDA filing triggers up to 30-month FDA approval stay
--------------------------------------------------------------------------------

- Dr. Reddy's sent an Oct. 1, 2026 notice that it filed an ANDA with a Paragraph IV certification for generic TONMYA (cyclobenzaprine HCl) sublingual tablets, 2.8 mg.
- Tonix filed a patent infringement complaint Nov. 13, 2026 in the U.S. District Court for the District of New Jersey against Dr. Reddy's Laboratories Ltd. and Dr. Reddy's Laboratories, Inc.
- Complaint asserts Orange Book patents 9,636,408; 9,956,188; 10,117,936; and 10,864,175, and seeks FDA approval no earlier than the last patent's expiration.
- Timely filing triggers a statutory stay of final FDA approval of Dr. Reddy's ANDA for up to 30 months, subject to exceptions and court orders.
- Tonix cautions that its patents could be found invalid, unenforceable or not infringed, and generic competition could hurt TONMYA sales.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000149315226051693/0001493152-26-051693-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000149315226051693/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-051693

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer